Cointime

Nouscom

company

About

Nouscom are a biotech company working to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells.

  • 1 - 10

Highlights

Total Funding Amount
€54M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Series B
Last Funding Money Raised
€42M
Industries
Biotechnology,Genetics,Health Care,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy.

The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€54M
Nouscom has raised a total of €54M in funding over 2 rounds. Their latest funding was raised on Nov 6, 2017 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 6, 2017 Series B €42M 1 — — Detail
May 17, 2016 Series A €12M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Nouscom is funded by 1 investors. Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures — Series B
Cointime
เนื้อหา
บริษัท